Novavax reports 90% efficacy:
Novavax will prioritise developing countries for the initial supplies of its Covid-19 vaccine, the Chief Executive Officer of the American biotechnology company said on Monday.
The Maryland-headquartered company said its vaccine had demonstrated 100 per cent protection in late-stage trials against moderate and severe disease caused by SARS-CoV-2 — a boost for the prospects of its Indian version, Covovax.Overall, the efficacy of the vaccine was 90.4 per cent.